Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.46
NAS:NBIX's Cash-to-Debt is ranked higher than
96% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:NBIX: 1.46 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:NBIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.46  Med: 44.18 Max: No Debt
Current: 1.46
Equity-to-Asset 0.46
NAS:NBIX's Equity-to-Asset is ranked lower than
99.99% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:NBIX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:NBIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.79 Max: 0.95
Current: 0.46
0.01
0.95
Debt-to-Equity 1.05
NAS:NBIX's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:NBIX: 1.05 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:NBIX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.06 Max: 16.07
Current: 1.05
0
16.07
Piotroski F-Score: 2
Altman Z-Score: 5.00
Beneish M-Score: -5.30
WACC vs ROIC
11.50%
-577.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3502.56
NAS:NBIX's Operating Margin % is ranked lower than
81% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:NBIX: -3502.56 )
Ranked among companies with meaningful Operating Margin % only.
NAS:NBIX' s Operating Margin % Range Over the Past 10 Years
Min: -17340.03  Med: -982.48 Max: 43.82
Current: -3502.56
-17340.03
43.82
Net Margin % -3470.51
NAS:NBIX's Net Margin % is ranked lower than
81% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:NBIX: -3470.51 )
Ranked among companies with meaningful Net Margin % only.
NAS:NBIX' s Net Margin % Range Over the Past 10 Years
Min: -16936.19  Med: -940.6 Max: 48.53
Current: -3470.51
-16936.19
48.53
ROE % -67.03
NAS:NBIX's ROE % is ranked lower than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:NBIX: -67.03 )
Ranked among companies with meaningful ROE % only.
NAS:NBIX' s ROE % Range Over the Past 10 Years
Min: -250.63  Med: -37.48 Max: 94.61
Current: -67.03
-250.63
94.61
ROA % -49.13
NAS:NBIX's ROA % is ranked lower than
66% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:NBIX: -49.13 )
Ranked among companies with meaningful ROA % only.
NAS:NBIX' s ROA % Range Over the Past 10 Years
Min: -62.22  Med: -28.37 Max: 26.57
Current: -49.13
-62.22
26.57
ROC (Joel Greenblatt) % -3396.74
NAS:NBIX's ROC (Joel Greenblatt) % is ranked lower than
78% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:NBIX: -3396.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:NBIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3396.74  Med: -928.61 Max: 2175.88
Current: -3396.74
-3396.74
2175.88
3-Year Revenue Growth Rate 57.80
NAS:NBIX's 3-Year Revenue Growth Rate is ranked higher than
89% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:NBIX: 57.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:NBIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -10.75 Max: 170.6
Current: 57.8
-100
170.6
3-Year EBITDA Growth Rate 32.00
NAS:NBIX's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:NBIX: 32.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:NBIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.3  Med: 31.05 Max: 109.6
Current: 32
-64.3
109.6
3-Year EPS without NRI Growth Rate 33.20
NAS:NBIX's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:NBIX: 33.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:NBIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.8  Med: 21.05 Max: 66.3
Current: 33.2
-69.8
66.3
GuruFocus has detected 4 Warning Signs with Neurocrine Biosciences Inc $NAS:NBIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:NBIX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NBIX Guru Trades in Q3 2016

George Soros 11,322 sh (New)
Jana Partners 96,210 sh (New)
Pioneer Investments 157,165 sh (-0.53%)
» More
Q4 2016

NBIX Guru Trades in Q4 2016

Jana Partners 181,296 sh (+88.44%)
George Soros Sold Out
Pioneer Investments 153,347 sh (-2.43%)
» More
Q1 2017

NBIX Guru Trades in Q1 2017

Steven Cohen 100,000 sh (New)
Pioneer Investments Sold Out
Jana Partners Sold Out
» More
Q2 2017

NBIX Guru Trades in Q2 2017

George Soros 4,900 sh (New)
Paul Tudor Jones 5,428 sh (New)
Steven Cohen 587,000 sh (+487.00%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-06-30 New Buy0.01%$40.24 - $54.65 $ 56.3316%4,900
George Soros 2016-12-31 Sold Out 0.02%$37.9 - $54.77 $ 56.3324%0
George Soros 2016-09-30 New Buy0.02%$45.29 - $54.63 $ 56.3313%11,322
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:UTHR, NAS:JUNO, NAS:TECH, NAS:ACAD, NAS:BIVV, NAS:BLUE, NAS:PBYI, NAS:FGEN, NAS:TSRO, NAS:NKTR, NAS:CLVS, NAS:AGIO, NAS:PTLA, NAS:ALNY, NAS:ONCE, NAS:SRPT, NAS:LGND, NAS:AVXS, NAS:IONS, NAS:LOXO » details
Traded in other countries:NB3.Germany,
Headquarter Location:USA
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Neurocrine Biosciences is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company has yet to launch a product and continues to accumulate significant operating losses. A now-canceled commercialization agreement with Pfizer accounted for 94% of revenue between 2003 and 2005 in the form of reimbursements and milestone payments.

Ratios

vs
industry
vs
history
PB Ratio 14.41
NBIX's PB Ratio is ranked lower than
90% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NBIX: 14.41 )
Ranked among companies with meaningful PB Ratio only.
NBIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 7.13 Max: 120
Current: 14.41
0.9
120
PS Ratio 782.36
NBIX's PS Ratio is ranked lower than
99.99% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. NBIX: 782.36 )
Ranked among companies with meaningful PS Ratio only.
NBIX' s PS Ratio Range Over the Past 10 Years
Min: 3.86  Med: 40.72 Max: 3581.82
Current: 782.36
3.86
3581.82
EV-to-EBIT -21.85
NBIX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. NBIX: -21.85 )
Ranked among companies with meaningful EV-to-EBIT only.
NBIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -165.9  Med: -8.3 Max: 426.3
Current: -21.85
-165.9
426.3
EV-to-EBITDA -22.06
NBIX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NBIX: -22.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
NBIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -636.6  Med: -8.9 Max: 293.3
Current: -22.06
-636.6
293.3
EV-to-Revenue 758.52
NBIX's EV-to-Revenue is ranked lower than
89% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. NBIX: 758.52 )
Ranked among companies with meaningful EV-to-Revenue only.
NBIX' s EV-to-Revenue Range Over the Past 10 Years
Min: -8.1  Med: 24.6 Max: 3856.2
Current: 758.52
-8.1
3856.2
Current Ratio 19.36
NBIX's Current Ratio is ranked higher than
80% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NBIX: 19.36 )
Ranked among companies with meaningful Current Ratio only.
NBIX' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.84 Max: 26.66
Current: 19.36
1.63
26.66
Quick Ratio 19.36
NBIX's Quick Ratio is ranked higher than
80% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. NBIX: 19.36 )
Ranked among companies with meaningful Quick Ratio only.
NBIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.84 Max: 26.66
Current: 19.36
1.63
26.66
Days Inventory 153.18
NBIX's Days Inventory is ranked lower than
99.99% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. NBIX: 153.18 )
Ranked among companies with meaningful Days Inventory only.
NBIX' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 153.18
Current: 153.18
0
153.18
Days Sales Outstanding 349.96
NBIX's Days Sales Outstanding is ranked lower than
99.99% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. NBIX: 349.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.58  Med: 8.97 Max: 349.96
Current: 349.96
3.58
349.96
Days Payable 5.00
NBIX's Days Payable is ranked lower than
99.99% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. NBIX: 5.00 )
Ranked among companies with meaningful Days Payable only.
NBIX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5
Current: 5
0
5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
NBIX's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NBIX: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NBIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17  Med: -9 Max: -1.3
Current: -8.9
-17
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 42.67
NBIX's Price-to-Net-Cash is ranked lower than
78% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. NBIX: 42.67 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NBIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.62  Med: 9.37 Max: 254.67
Current: 42.67
2.62
254.67
Price-to-Net-Current-Asset-Value 38.85
NBIX's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. NBIX: 38.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NBIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.79  Med: 6.71 Max: 280
Current: 38.85
1.79
280
Price-to-Tangible-Book 14.41
NBIX's Price-to-Tangible-Book is ranked lower than
85% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NBIX: 14.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NBIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.11  Med: 4.92 Max: 112.96
Current: 14.41
1.11
112.96
Price-to-Median-PS-Value 19.23
NBIX's Price-to-Median-PS-Value is ranked lower than
99.99% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NBIX: 19.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NBIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.62 Max: 35.61
Current: 19.23
0.09
35.61
Earnings Yield (Greenblatt) % -4.58
NBIX's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. NBIX: -4.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NBIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2432.5  Med: -4.4 Max: 3530
Current: -4.58
-2432.5
3530

More Statistics

Revenue (TTM) (Mil) $6.34
EPS (TTM) $ -2.53
Beta1.55
Short Percentage of Float12.40%
52-Week Range $37.35 - 60.00
Shares Outstanding (Mil)88.22

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 70 186 392 784
EPS ($) -2.24 -2.26 -0.53 2.26
EPS without NRI ($) -2.24 -2.26 -0.53 2.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:NBIX

Headlines

Articles On GuruFocus.com
Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Pres Sep 15 2017 
Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Sep 06 2017 
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Sep 06 2017 
5 Health Care Companies Gurus Are Buying Sep 05 2017 
Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference Aug 30 2017 
Neurocrine Biosciences Reports Second Quarter 2017 Results Aug 03 2017 
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results Jul 28 2017 
Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer Jul 21 2017 
Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference Jun 09 2017 
Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st Internat Jun 02 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Sep 18 2017
Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be... Sep 15 2017
Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Sep 06 2017
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the... Sep 06 2017
Behind Bioverativ’s Analyst Recommendations This September Sep 06 2017
Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference Aug 30 2017
Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82 Aug 30 2017
Today's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine... Aug 25 2017
Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT Aug 12 2017
IHS Markit Score downgrades Neurocrine Biosciences Inc to 12 out of 100, ranking negatively in two... Aug 11 2017
IHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in... Aug 10 2017
Featured Company News - Mylan Launches Avonza(TM) in India Aug 10 2017
Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics Aug 07 2017
NBIX: Strong Start to INGREZZA® Launch Aug 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}